Raymond James Financial
UTHR icon

Raymond James Financial’s United Therapeutics UTHR Stock Holding History

Raymond James Financial’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.9M Buy
55,173
+7,597
+16% +$4.28M 0.01% 1281
2026
Q1 		$28.2M Sell
47,576
-901
-2% -$449K 0.01% 1231
2025
Q4 		$23.6M Buy
48,477
+5,509
+13% +$2.57M 0.01% 1325
2025
Q3 		$18M Sell
42,968
-2,890
-6% -$972K 0.01% 1487
2025
Q2 		$13.2M Sell
45,858
-9,687
-17% -$2.9M ﹤0.01% 1666
2025
Q1 		$17.1M Buy
55,545
+3,801
+7% +$1.3M 0.01% 1426
2024
Q4 		$18.3M Buy
+51,744
New +$19M 0.01% 1395

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Raymond James Financial's UTHR Position: Q2 2026 in Review

Raymond James Financial increased its United Therapeutics (UTHR) stake by 16% in Q2 2026, buying an estimated $4.28M and bringing the position to 55,173 shares worth $29.9M. The position accounts for 0.01% of the portfolio, ranked #1281.

Raymond James Financial first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Raymond James Financial held 55,173 shares of United Therapeutics worth $29.9M as of Q2 2026.
  • Raymond James Financial bought 7,597 United Therapeutics shares in Q2 2026, an estimated $4.28M.
  • United Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #1281 holding.
  • Raymond James Financial first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.